Caitong International Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Caitong International Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,476	Closed	-$124K	–	3106
2026 Q1	$124K	Buy	1,476 +429	+41%	+$24.8K	0.02%	524
2025 Q4	$43.1K	Buy	+1,047	New	+$40.6K	0.01%	759
2025 Q3	–	Sell	-356	Closed	-$6.63K	–	2079
2025 Q2	$6.63K	Buy	+356	New	+$6.68K	﹤0.01%	891
2025 Q1	–	Sell	-13	Closed	-$283	–	2250
2024 Q4	$283	Buy	+13	New	+$334	﹤0.01%	1548

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Caitong International Asset Management's DNTH Position: Q2 2026 in Review

Caitong International Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 1,476 shares — an estimated $124K sold.

Caitong International Asset Management first reported a position in DNTH in Q4 2024 and held it in 4 quarters. The position peaked at $124K in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Caitong International Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
Caitong International Asset Management sold 1,476 Dianthus Therapeutics shares in Q2 2026, an estimated $124K.
Caitong International Asset Management first reported a position in Dianthus Therapeutics in Q4 2024 and held it in 4 quarters.
Caitong International Asset Management's Dianthus Therapeutics position peaked at $124K in Q1 2026.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.